1st Working Groups Meeting – 2nd CG & MC – Training School Málaga 14-15 March 2019

09/23/2018 Aurelie Papineau

1^st Working Groups Meeting, 2nd CG & MC – Training School.

Málaga 14-15 March 2019

Venue

Aula Magna, School of Medicine, Boulevard Louis Pasteur, 32. Campus de Teatinos S/N. 29010 Málaga.

Hotel

Hotel Ibis Málaga Centro

COST IBIS ACCOMMODATION FORM

Scientific programmes

Working groups Meeting

1st Working Groups Meeting

Date: 14 March 2019

Time: 08.30h to 18.30h

Venue: Aula Magna, School of Medicine, Blvd L Pasteur 32, 29071. Málaga, Spain

8.30 Registration

8.45 – 9.15 PRO-EURODILI Welcome

9.15-9.45 Chair: Raul J Andrade, Spain

Plenary Lecture: Michael Manns, Germany

How European hepatologists can benefit from the Pro Euro DILI Net Cost?

10.00-11.00 Short presentations from WGs Leaders

Speakers:

WG1 Prof. Jane Groove, Nottingham, UK

WG2 Prof. Gerd A Kullak Ublick, Switzerland

WG3 Prof. José Carlos Fernández Checa, Spain

WG4 Prof. Einar Stefán Björnsson, Iceland

WG5 Dr Simona Stankevičiūtė, Lithuania

11:00- 11:20 Coffee Break

11.20-12.30 Break-out Sessions: WGs Meeting

Each WG Leader: Introduction, Tour de Table

Aims, tasks & Deliverables

12.30-13.00 Chair: Guruprasad Aithal

Plenary Lecture: Ann Daly, Newcastle, UK

DILI as a polygenic disease. International Consortia and DILI initiatives to strengthen knowledge development

13.00-14.30 Lunch Break

14.30-15.00 Chair: Carmen Peralta, Spain

Plenary Lecture: Leo Nelson, Edinburgh, Scotland

Human Models for improved prediction of DILI

15.00-16.45 Break-out sessions

WG1, WG2, WG3, WG4, WG5

16.45-17.00 Coffee Break

17.00-17.30 Chair: Joanna Miranda, Portugal

Plenary Lecture

Andreas Benesic, Munich, Germany

Outreaching biotechnological enterprises in DILI

17.30-18.30 Plenary session (results and conclusion) All

2nd Core Group Meeting

COST Action CA17112

Action Title: Prospective European Drug-Induced Liver Injury Network

Draft Agenda

Second Core Group Meeting

Málaga, Spain

15th March 2019

08:30 – 10:00

Venue: Biblioteca Departamento de Farmacología, Facultad de Medicina, Málaga

Approval of CG#1 minutes (2019 January 9^th, Lisbon, Portugal)
Report about PRO EURO DILI NET management tasks and Implementation of COST policies
Internal evaluation of the 1st Grant Period
Discussion about management rules for activities 2019/20
1. STSMs
2. Training schools (survey)
3. ITC Conference Grant
4. Monothematic Conference planning
Action implementation planning
1. Monitoring of the Objective Achievement Indicators for MoU Objectives
2. Activity and budget planning (Work and Budget Plan preparation)
3. Dissemination strategy/ planning (Publications and outreach activities)
Any Other Business
Closing

2nd Management Committee Meeting

COST Action CA17112

Action Title: Prospective European Drug-Induced Liver Injury Network

Draft Agenda

Management Committee Meeting

Málaga, Spain

15th March 2019.

10:30 – 13:00

Venue: Seminar, Department of Pharmacology, School of Medicine.

Welcome to participants
Verification of the presence of two-thirds of the Participating COST Countries or, if applicable, a quorum
Adoption of agenda
Approval of minutes and matters arising of last meeting
Update from the Action Chair
a) Status of Action: start and end dates of Action, participating COST countries, participating NNC/ IPC institutions and Specific Organisations.
b) Short Term Scientific Missions (STSM): List of centres, topics, dates and ready to take applications
c) Training Schools: Rules and topics
Update from the Grant Holder: Action budget status
Update from the COST Association: Science officer and Administrative Officer
Monitoring of the Action
Implementation of COST policies on:
a) Promotion of gender balance and Early Career Investigators (ECI)
b) Inclusiveness and Excellence (see below list of Inclusiveness Target Countries)
Follow-up of MoU objectives: progress report of working groups
Scientific planning
a) Scientific strategy (MoU objectives, GP Goals, WG tasks and deliverables)
b) Action Budget Planning
c) Long-term planning (including anticipated locations and dates of future activities)
d) Dissemination planning (Publications and outreach activities)
Requests to join the Action from:
a) COST countries
b) Institutions in Near Neighbouring Countries, International Partner Countries, and/or Specific Organisations
AOB
Location and date of next meeting
Summary of MC decisions
Closing

Training School

1^st TRAINING COURSE, ACTION COST 17-112

PRO EURO DILI NET

ASSESSMENT OF DRUG-INDUCED LIVER INJURY: KEY RULES AND COMMON PITFALLS. HOW TO MAKE A CLINICAL NARRATIVE

We are currently working in order to achieve ERT (Eurotox) recognition for the course.

Date: 15 March 2019

Time: 08.30h to 19.00h

Venue: Aula Magna, School of Medicine, Blvd L Pasteur 32, 29071. Málaga, Spain

Registration form: https://goo.gl/forms/MspTgxQb4ts3NSNJ3

Overview

Idiosyncratic drug-induced liver injury (DILI) is an acute adverse hepatic reaction that occurs in only a small proportion of individuals exposed to a drug, it is unexpected from the known pharmacological action of the agent, leading to illness, disability, hospitalization, including life threatening liver failure and death or need for liver transplantation. DILI represents a major challenge for clinicians, the pharmaceutical industry and regulatory agencies worldwide as it stands as one of the main causes of drug attrition during development and the adoption of regulatory measures to improve clinical safety. There is a clear need for a deeper understanding of this complex and intriguing disorder.

To achieve this objective regulatory bodies and professionals from the pharmacovigilance arena should develop skills in DILI recognition through an update on the key criteria used for DILI diagnosis and its in-depth phenotyping. This course will combine conceptual talks with problem-solving learning exercises to help translate the knowledge into a real world setting.

Learning Objectives

This training course in DILI will enable to

Make a proper DILI case definition and phenotype classification and a case narrative
Recognize the drugs most commonly involved in DILI and the scientific evidence to support it
Work-out the minimal elements to make a proper DILI case adjudication
Balance the value of the diagnostic scales used for DILI assessment
Recognize the role of liver tests monitoring in preventing/minimizing DILI risk

Assessment

The assessment is based on a written MCQ examination on the last day of the course

Scientific Program (Agenda)

Day 15 March 2019

08.30 REGISTRATION

08.45h Introduction, opening statements and presentations

Raúl J Andrade

09.00 / 09.30 Risk Minimization Strategies. Why DILI initiative is important?

Herve Le Louet, France

09.30 / 10.00 Drug-induced liver injury: general concepts, interpretation of liver tests and common mistakes.

Raúl J Andrade, Spain

10.00 /10.30 COFFEE BREAK